BioLingus AG - Product Pipeline Review - 2016

  • ID: 4035462
  • Company Profile
  • 30 pages
  • Global Markets Direct
1 of 4
BioLingus AG - Product Pipeline Review - 2016

Summary

‘BioLingus AG - Product Pipeline Review - 2016’, provides an overview of the BioLingus AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by BioLingus AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of BioLingus AG
- The report provides overview of BioLingus AG including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses BioLingus AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features BioLingus AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate BioLingus AG’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for BioLingus AG
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding BioLingus AG’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

BioLingus AG Snapshot

BioLingus AG Overview

Key Facts

BioLingus AG - Research and Development Overview

Key Therapeutic Areas

BioLingus AG - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

BioLingus AG - Pipeline Products Glance

BioLingus AG - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

BioLingus AG - Unknown Stage Pipeline Products

Unknown Products/Combination Treatment Modalities

BioLingus AG - Drug Profiles

aldesleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target Survivin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exenatide biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon gamma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interleukin 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize GLP-1 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit TNF-Alpha for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BioLingus AG - Pipeline Analysis

BioLingus AG - Pipeline Products by Target

BioLingus AG - Pipeline Products by Route of Administration

BioLingus AG - Pipeline Products by Molecule Type

BioLingus AG - Pipeline Products by Mechanism of Action

BioLingus AG - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

BioLingus AG, Key Facts

BioLingus AG - Pipeline by Indication, 2016

BioLingus AG - Pipeline by Stage of Development, 2016

BioLingus AG - Monotherapy Products in Pipeline, 2016

BioLingus AG - Preclinical, 2016

BioLingus AG - Discovery, 2016

BioLingus AG - Unknown, 2016

BioLingus AG - Pipeline by Target, 2016

BioLingus AG - Pipeline by Route of Administration, 2016

BioLingus AG - Pipeline by Molecule Type, 2016

BioLingus AG - Pipeline Products by Mechanism of Action, 2016

List of Figures:

BioLingus AG - Pipeline by Top 10 Indication, 2016

BioLingus AG - Pipeline by Stage of Development, 2016

BioLingus AG - Monotherapy Products in Pipeline, 2016

BioLingus AG - Pipeline Target, 2016

BioLingus AG - Pipeline by Route of Administration, 2016

BioLingus AG - Pipeline by Molecule Type, 2016

BioLingus AG - Pipeline Products by Mechanism of Action,
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll